This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug in the European Union led to an assessment of the health and social risks posed by the substance, and, consequently, its control across the EU Member States.

Table of contents:
• Foreword
• Introduction
• EMCDDA actions on monitoring and responding to new drugs
• EMCDDA–Europol Joint Report on 4-methylamphetamine: a summary
• Risk Assessment Report of a new psychoactive substance: 4-methylamphetamine
• Annex 1: Technical report on 4-methylamphetamine
• Annex 2: Computational analysis on the pharmacology of 4-methylamphetamine
• Council Decision 2013/129/EU on subjecting 4-methylamphetamine to control measures
• Abbreviations
• Participants of the risk assessment meeting